Published in Nat Rev Nephrol on February 21, 2012
REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs (RECORDER) | NCT02950389
Kidney diseases associated with haematological cancers. Nat Rev Nephrol (2015) 0.83
Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment. Blood Cancer J (2014) 0.75
Removal of free light chains in hemodialysis patients without multiple myeloma: a crossover comparison of three different dialyzers. BMC Nephrol (2016) 0.75
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem (2001) 3.94
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med (2005) 2.67
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med (2011) 2.42
Nephrotoxic potential of Bence Jones proteins. N Engl J Med (1991) 2.24
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol (2000) 2.15
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica (2007) 2.10
Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol (2008) 2.08
Serum free light chains for monitoring multiple myeloma. Br J Haematol (2004) 2.07
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol (2005) 1.97
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol (2007) 1.89
Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med (1998) 1.79
The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest (1972) 1.70
Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int (2006) 1.68
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood (2006) 1.63
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant (2012) 1.62
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma (2008) 1.61
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol (2011) 1.57
Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol (2007) 1.54
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer (2005) 1.50
Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann Hematol (2009) 1.47
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int (2005) 1.46
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Biosynthesis of immunoglobulins. Free light chain as an intermediate in the assembly of gamma G-molecules. Nature (1966) 1.43
Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol (2001) 1.42
Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest (1992) 1.40
The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol (2011) 1.38
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol (2010) 1.38
Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant (1998) 1.34
Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol (2009) 1.30
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica (2007) 1.30
Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med (1990) 1.26
Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol (1995) 1.24
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol (2007) 1.21
Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest (1991) 1.19
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer (2010) 1.16
Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med (1991) 1.15
Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med (1990) 1.13
Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int (1988) 1.11
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma (2009) 1.11
Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol (2005) 1.08
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol (2009) 1.07
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res (2010) 1.06
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol (2009) 1.05
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol (2003) 1.05
Acute myeloma kidney. Kidney Int (1995) 1.05
Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs (2008) 1.04
Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion (2007) 1.03
The clinical spectrum of light chain myeloma. A study of 35 patients with special reference to the occurrence of amyloidosis. Am J Med (1975) 1.02
Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism. Blood (2010) 1.02
Monoclonal immunoglobulin light chain-related renal diseases. Semin Nephrol (1993) 1.00
Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant (2009) 1.00
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol (2003) 0.99
High cut-off dialysis membranes: current uses and future potential. Adv Chronic Kidney Dis (2011) 0.98
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant (2004) 0.97
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol (2010) 0.96
European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials (2008) 0.94
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. Biol Blood Marrow Transplant (2010) 0.91
Factors influencing the prognosis in myelomatosis. Postgrad Med J (1971) 0.90
Pathogenesis and treatment of myeloma kidney. J Lab Clin Med (1994) 0.90
Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J (2000) 0.90
Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol (2010) 0.88
Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. Eur J Haematol (2010) 0.86
Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis. Nephrol Dial Transplant (2011) 0.86
Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease? Expert Opin Ther Targets (2008) 0.86
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol (2004) 0.85
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma (2008) 0.85
Multiple myeloma and renal failure: one center's experience. Ren Fail (1998) 0.83
Renal impairment in patients with multiple myeloma. Hong Kong Med J (2003) 0.82
Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol (2004) 0.81
Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology. Clin Lymphoma Myeloma (2007) 0.80
Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study. Nephrol Dial Transplant (2011) 0.79
Paraproteinemic renal diseases that involve the tubulo-interstitium. Contrib Nephrol (2007) 0.78
Factors of prognostic significance in myelomatosis. J Clin Pathol (1972) 0.77
Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Semin Hematol (2005) 0.77
Bence Jones proteinuria and myeloma kidney. Nephrol Dial Transplant (1996) 0.76
Management of myeloma kidney: an anti-light-chain approach. Am J Kidney Dis (1987) 0.76
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
An epidemic of chronic kidney disease: fact or fiction? Nephrol Dial Transplant (2008) 7.23
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. N Engl J Med (2002) 5.24
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol (2005) 4.69
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood (2008) 2.74
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood (2006) 2.51
Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med (2011) 2.42
Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol (2008) 2.41
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood (2012) 2.39
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38
IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol (2010) 2.35
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol (2008) 2.30
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res (2007) 2.19
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood (2009) 2.19
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol (2008) 2.09
Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica (2002) 2.08
Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol (2008) 2.08
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis (2009) 2.00
The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int (2008) 1.94
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol (2008) 1.89
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 1.89
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol (2012) 1.87
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol (2013) 1.79
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int (2013) 1.79
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma (2010) 1.78
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol (2011) 1.78
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood (2012) 1.75
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol (2006) 1.75
Chronic renal dysfunction late after liver transplantation. Liver Transpl (2002) 1.74
Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis (2003) 1.73
Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J (2002) 1.72
A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis (2006) 1.70
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol (2013) 1.70
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 1.65
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol (2009) 1.64
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant (2012) 1.62
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int (2011) 1.62
Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med (2006) 1.61
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma (2008) 1.61
Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol (2011) 1.58
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol (2003) 1.57
Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. Crit Care (2014) 1.57
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol (2011) 1.57
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant (2009) 1.56
Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol (2007) 1.54
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma (2008) 1.54
Diagnosis of monoclonal gammopathy of renal significance. Kidney Int (2015) 1.53
Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc (2009) 1.53
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol (2008) 1.53
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc (2011) 1.53
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol (2008) 1.52
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood (2006) 1.51
Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci (2004) 1.51
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol (2004) 1.51
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica (2006) 1.49
Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev (2010) 1.48
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res (2009) 1.47
Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int (2012) 1.45
The association between life events, social support, and antibody status following thymus-dependent and thymus-independent vaccinations in healthy young adults. Brain Behav Immun (2004) 1.45
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma (2006) 1.44